

India's generics market to touch \$26.1 bn by 2016, IBEF reports

23 September 2015 | Reports/white papers | By BioSpectrum Bureau

India's generics market to touch \$26.1 bn by 2016, IBEF reports



India's pharmaceutical industry is expected to expand at a CAGR of 14.5 percent over 2009-20 to reach \$55 billion, according to a report by India Brand Equity Foundation (IBEF).

The Indian healthcare sector, considered as one of the fastest growing sectors, is expected to advance at a CAGR of 17 percent to reach \$280 billion over 2011-20.

As a major generics market, the country is expected to grow to \$26.1 billion by 2016 from \$11.3 billion in 2011. India's generics market has immense potential for growth, IBEF said.

In terms of biosimilars, India's biosimilars sector is expected to touch \$1.4 billion by 2016 from \$482 million in 2011. The Indian government plans to allocate \$70 million for local players in the country to develop biosimilars.

Click here to view or download the full report.